Headlands Technologies’s Axsome Therapeutics AXSM Stock Holding History

Headlands Technologies’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,187	Closed	-$947K	–	735
2025 Q4	$947K	Buy	5,187 +2,613	+102%	+$365K	0.08%	275
2025 Q3	$313K	Buy	2,574 +2,476	+2,527%	+$279K	0.03%	455
2025 Q2	$10.2K	Buy	+98	New	+$10.4K	﹤0.01%	1009
2024 Q2	–	Sell	-102	Closed	-$8.14K	–	1152
2024 Q1	$8.14K	Buy	102 +24	+31%	+$2.01K	﹤0.01%	1050
2023 Q4	$6.21K	Sell	78 -312	-80%	-$20.9K	﹤0.01%	810
2023 Q3	$27.3K	Buy	390 +65	+20%	+$4.86K	0.01%	541
2023 Q2	$23.4K	Buy	+325	New	+$24K	0.01%	546

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Headlands Technologies's AXSM Position: Q1 2026 in Review

Headlands Technologies sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 5,187 shares — an estimated $947K sold.

Headlands Technologies first reported a position in AXSM in Q2 2023 and held it in 7 quarters. The position peaked at $947K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Headlands Technologies reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Headlands Technologies sold 5,187 Axsome Therapeutics shares in Q1 2026, an estimated $947K.
Headlands Technologies first reported a position in Axsome Therapeutics in Q2 2023 and held it in 7 quarters.
Headlands Technologies's Axsome Therapeutics position peaked at $947K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.